Lundbeck Canada, a subsidiary of H Lundbeck, has reported that Lu AE58054 met its primary cognition endpoint in a Phase 2, proof-of-concept study of Alzheimer’s disease.

The investigational Alzheimer’s drug, Lu AE58054, is a potent and selective 5-HT6 receptor antagonist.

Lundbeck Canada scientific affairs senior director, Jean Proulx, said: "We see Lu AE58054 as having a strong potential in Alzheimer’s disease, a disease with a huge unmet medical need."

"Patients receiving the investigational compound achieved statistically significant improvement in cognition."

The study was conducted in 278 patients in Canada, Europe and Australia, with either Lu AE58054 (plus 10mg a day donepezil) or placebo (plus 10mg a day donepezil).

Patients receiving the investigational compound achieved statistically significant improvement in cognition, as measured by the Alzheimer’s Disease Assessment Scale-cognitive sub-scale (ADAS-cog) over a 24-week treatment period versus donepezil monotherapy (10mg a day).

Measures of global status and activities of daily living, which were the secondary endpoints of the trial, also showed positive trends with the addition of Lu AE58054, compared with patients who received donepezil alone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Treatment with augmentation therapy Lu AE58054 was well tolerated in the study, according to the company.

Toronto Memory Program medical director and behavioural neurologist, Sharon Cohen, said that as the Canadian population ages, effective and safe treatments that can help reduce Alzheimer’s symptoms are becoming increasingly crucial.

"It is encouraging to see these positive preliminary results and it will be interesting to follow this compound’s development," Cohen added.

Lundbeck intends to initiate a major pivotal clinical programme of Lu AE58054, potentially including development and commercial partnerships.